Breast cancer patients presenting with cardiotoxicity - risk factors and role of cardioprotective drugs
In: European Heart Journal - Cardiovascular Imaging ; volume 23, issue Supplement_1 ; ISSN 2047-2404 2047-2412, 2022
Online
academicJournal
Zugriff:
Funding Acknowledgements Type of funding sources: None. Introduction Recent advances in cancer treatment have led to improved survival, albeit with cardiovascular adverse effects being some of the most frequent and feared consequences. Patient’s risk stratification, prevention and treatment are still to be fully elucidated. Our aim was to evaluate the risk and therapy of cardiotoxicity (CT) secondary to cancer treatment in a subset of patients with breast cancer (BC). Methods We collected a retrospective cohort of female with BC treated with conventional chemotherapy (CHT) and/or anti-HER2-targeted therapies (AHT) referred to Cardio-oncology consultation from January 2017 to March 2020. All patients were evaluated before CHT and at least at 3, 6 and 12-months with echocardiogram and cardiac biomarkers, namely high sensitivity troponin I (hs-cTnI) and brain natriuretic peptide (BNP). CT was defined as left ventricle ejection fraction (LVEF) under 50% or decline of at least 10% in LVEF during follow-up. As cardioprotective drugs (CPD) we considered renin-angiotensin-aldosterone system inhibitors and beta-blockers. Results A total of 203 women were enrolled, with mean age 50.9 ± 10.9 year-old. As for the cardiovascular risk factors, 23.5% had hypertension, 32.4% dyslipidaemia, 9.8% diabetes and 33.0% were smokers or previous smokers. The majority of patients had a high or very-high CT risk score (98.5% with score ≥ 5) and 35.5% were already on CPD before CHT. All patients were submitted to CHT: anthracyclines (AC) and AHT were applied to 83.8% and 41.7% of patients, respectively, with 27.9% of patients on both therapies; 81.4% were submitted to radiotherapy (RT). At presentation, all patients had normal cardiac function with mean LVEF of 62.9% and mean global longitudinal strain (GLS) of -19.4; mean hs-cTnI and BNP were 3.3 ng/L and 33.4 pg/mL, respectively. During a median follow-up of 16 months, 8.5% of patients developed CT, leading to initiation or titration of CPD in 76.9% and treatment interruption ...
Titel: |
Breast cancer patients presenting with cardiotoxicity - risk factors and role of cardioprotective drugs
|
---|---|
Autor/in / Beteiligte Person: | Martins De Carvalho, M ; Proenca, T ; Pinto, RA ; Costa, I ; Torres, S ; Resende, CX ; Grilo, PD ; Amador, AF ; Costa, C ; Calvao, J ; Cabrita, A ; Marques, C ; Sousa, C ; Paiva, M ; Macedo, F |
Link: | |
Zeitschrift: | European Heart Journal - Cardiovascular Imaging ; volume 23, issue Supplement_1 ; ISSN 2047-2404 2047-2412, 2022 |
Veröffentlichung: | Oxford University Press (OUP), 2022 |
Medientyp: | academicJournal |
DOI: | 10.1093/ehjci/jeab289.020 |
Schlagwort: |
|
Sonstiges: |
|